SQZ Biotech
Watertown
About SQZ Biotech
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $229.8M
- Funding stage: IPO
- Last round: Grant (Mar 2022)
- Ticker: nyse:SQZ
- Website: sqzbiotech.com
- Phone: 617-758-8672
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/sqz-biotech-86304 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.